ERBB2 and oral lichen planus: In 2015, Kouhsoltani et al. [29] showed that the lack of Her-2/neu (as a protein of EGFR family) overexpression indicates that molecular targeting of Her-2/neu protein is not recommended as adjuvant therapy in OSCC and OLP.